University of the Sciences Launches Cannabis MBA Program
University of the Sciences announced a new program for students interested in the cannabis industry: a specialized Cannabis Industry Masters of Business Administration (MBA) option.
University of the Sciences (USciences, Philadelphia, Pennsylvania) announced a new program for students interested in the cannabis industry: a specialized Cannabis Industry Masters of Business Administration (MBA) option (1). Enrollment is currently open with online courses set to begin in September.
According the University, the coursework is an option of USciences’ specialized MBA in pharmaceutical and healthcare business, which is a hybrid curriculum with students taking courses online with occasional visits to campus. The “Cannabis Industry Option” MBA is reportedly the first of its kind in the U.S., offering education in the business of cannabis, hemp, and dispensary operations. The cannabis option was created in partnership with USciences’ Substance Use Disorders Institute as well as feedback from individuals in the industry. The option includes four elective courses specific to medical cannabis regulations and industry such as “Introduction to the Medical Cannabis Industry;” “Finance and Regulation in the Medical Cannabis Industry;” and “Cannabis Marketing and Sales.” There is also a project-based course where students will work to write a business plan or bring a product to market.
Andrew Peterson, executive director of the Substance Use Disorders Institute, who was integral in the creation of the courses explained that there are many unique aspects to the medical cannabis and hemp industries. “This new program will help to formalize those teachings for those currently in the cannabis industry, entering the field, or interested in other fields associated with the industry,” said Peterson.
“As the industry grows, and the potential for medical cannabis to converge with the pharmaceutical industry, a specialization in pharmaceutical and healthcare business will be an asset to those in the cannabis industry,” said Peterson. “A combination of healthcare, pharmaceutical, and cannabis business knowledge and expertise will be incredibly valuable as graduates move forward in their career.”
For more information about this new program visit usciences.edu/CannabisMBA (2).
References:
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
